摘要
目的探究白蛋白结合型紫杉醇(Abraxane)、奥沙利铂联合治疗对晚期乳腺癌患者的疗效及血清黏蛋白1(MUC1)、细胞黏附分子变异体6(CD44v6)、血管内皮生长因子(VEGF)的影响。方法回顾性分析2015年4月至2018年9月湖南省妇幼保健院乳腺外科收治的晚期三阴乳腺癌患者112例作为研究对象,根据随机数字表法分为观察组(n=56)与对照组(n=56)。对照组采用Abraxane治疗,观察组采用Abraxane联合奥沙利铂治疗,3周一个疗程,治疗4个疗程。观察两组临床疗效,治疗12周后血清MUC1、CD44v6、VEGF水平,生活质量及安全性。结果观察组总有效率82.1%,高于对照组(58.9%),差异有统计学意义(P<0.05)。治疗12周后,观察组MUC1、CD44v6水平为(98.47±7.24)、(203.79±10.51)pg/mL,低于对照组[(121.48±7.35)、(289.64±11.57)pg/mL],VEGF水平为(195.33±16.75)pg/mL,高于对照组[(159.07±15.61)pg/mL],差异均有统计学意义(P<0.05)。观察组国内活动、家庭关系、心理状态、工作与经济形势得分分别为(16.36±2.47)、(20.84±2.41)、(18.82±2.53)、(15.29±1.68)分,均高于对照组[(11.33±2.25)、(15.61±2.08)、(14.60±2.71)、(11.77±1.99)分],差异均有统计学意义(P<0.05)。观察组Ⅲ~Ⅳ级中粒细胞减少发生率23.2%、血小板减少16.1%、血红蛋白减少10.7%,对照组依次为26.8%、17.9%、12.5%,两组不良反应比较,差异无统计学意义(P>0.05)。结论Abraxane联合奥沙利铂治疗晚期乳腺癌患者临床效果较好,有利于降低MUC1、CD44v6水平,提高VEGF水平,且不良反应较小。
Objective To investigate the efficacy of combination of Abraxane and oxaliplatin in patients with advanced breast cancer and its effect on serum mucin 1(MUC1),cluster of differentiation 44 variant 6(CD44v6),vascular endothelial growth factor(VEGF).Methods A total of 112 patients with advanced triple negative breast cancer(TNBC)admitted to a hospital from April 2015 to September 2018 were divided into observation group(n=56,Abraxane and oxaliplatin)and control group(n=56,conventional therapy)according to the random number table method.After 4 courses of treatment(3 weeks per course of treatment),the efficacy,serum MUC1,CD44v6,VEGF levels,quality of life and safety of the two groups were observed.Results The total effective rate of the observation group(82.1%)was higher than that of the control group(58.9%),the difference was statistically significant(P<0.05).After 12 weeks of treatment,the levels of MUC1 and CD44v6 in the observation group were(98.47±7.24)and(203.79±10.51)pg/mL,which were lower than those in the control group[(121.48±7.35),(289.64±11.57)pg/mL],and the level of VEGF was(195.33±16.75)pg/mL,which was higher than that in the control group[(159.07±15.61)pg/mL],and the differences were statistically significant(P<0.05).The scores of domestic activities,family relations,mental state,work and economic situation of the observation group were(16.36±2.47),(20.84±2.41),(18.82±2.53),(15.29±1.68)points,which were higher than those of the control group[(11.33±2.25),(15.61±2.08),(14.60±2.71),(11.77±1.99)points],the differences were statistically significant(P<0.05).The incidence of grade III-IV neutropenia in the observation group was 23.2%,thrombocytopenia was 16.1%,and hemoglobin was reduced by 10.7%.In the control group,they were 26.8%,17.9%and 12.5%.There were no statistically significant differences in adverse reactions between the two groups(P>0.05).Conclusion Abraxane combined with oxaliplatin is effective in patients with advanced breast cancer,which is beneficial to reduce the levels of MUC1 and CD44v6,increase the level of VEGF,and has fewer adverse reactions.
作者
段甚佳
尹红
陈杏初
DUAN Shen-jia;YIN Hong;CHEN Xing-chu(Department of Breast Surgery,Maternal and Child Health Hospital of Hunan Province,Changsha Hunan 410000,China)
出处
《临床和实验医学杂志》
2021年第22期2416-2419,共4页
Journal of Clinical and Experimental Medicine
基金
湖南省卫计委科研计划资助项目(编号:B2017040)。
